Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Argenica (ASX:AGN) share price leapt 12% on US patent news today
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
|20 May 2022||$0.50||$-0.03||-5.66%||77,378||$0.54||$0.55||$0.50|
|19 May 2022||$0.53||$0.04||8.16%||96,798||$0.48||$0.53||$0.46|
|18 May 2022||$0.49||$0.03||6.45%||44,759||$0.47||$0.51||$0.47|
|17 May 2022||$0.47||$0.00||0.00%||31,717||$0.48||$0.52||$0.45|
|16 May 2022||$0.47||$0.04||9.30%||978||$0.47||$0.47||$0.47|
|13 May 2022||$0.43||$0.01||2.38%||203,373||$0.43||$0.43||$0.40|
|12 May 2022||$0.42||$0.01||2.41%||67,882||$0.43||$0.43||$0.42|
|11 May 2022||$0.42||$-0.01||-2.35%||35,122||$0.43||$0.43||$0.42|
|10 May 2022||$0.43||$0.00||0.00%||268,466||$0.45||$0.45||$0.39|
|09 May 2022||$0.43||$-0.06||-12.50%||101,009||$0.45||$0.45||$0.43|
|06 May 2022||$0.48||$0.02||4.30%||96,170||$0.49||$0.49||$0.48|
|05 May 2022||$0.47||$0.03||6.82%||180,101||$0.46||$0.50||$0.46|
|04 May 2022||$0.44||$0.03||7.23%||254,965||$0.42||$0.44||$0.39|
|03 May 2022||$0.42||$-0.01||-2.35%||251,667||$0.43||$0.44||$0.42|
|02 May 2022||$0.43||$-0.04||-8.70%||112,960||$0.47||$0.47||$0.42|
|29 Apr 2022||$0.46||$0.01||2.22%||217,945||$0.48||$0.53||$0.45|
|28 Apr 2022||$0.45||$-0.07||-13.46%||129,417||$0.52||$0.52||$0.45|
|27 Apr 2022||$0.52||$-0.01||-1.89%||219,117||$0.51||$0.55||$0.50|
|26 Apr 2022||$0.53||$0.00||0.00%||79,384||$0.55||$0.55||$0.53|
|25 Feb 2022||Terrence (Terry) Budge||Buy||32||$20,786|| |
|Ms Elizabeth (Liddy) McCall||Non-Executive Director||Dec 2020|| |
Ms McCall is co-founder of 3 biotechnology companies successfully achieving 3 FDA drug registrations and 1 FDA/CE Mark medical device approval. She is an inventor on patents granted in major jurisdictions translating novel G-protein coupled pharmacology into a therapeutic drug treatment currently in Phase 2 clinical trials. Liddy cofounded IIF venture capital fund, Yuuwa Capital LP, which is responsible for a portfolio of 6 companies commercializing biotechnology and IT innovation. Liddy has over 25 years of experience in senior Board and management roles including Adalta Ltd, iCeutica Inc group, Dimerix Bioscience Pty Ltd and iCetana Pty Ltd. Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm. Liddy is a non-executive director of the not-for profit Ear Science Institute Australia and also of Agworld Pty Ltd, Nexgen Plants Pty Ltd and The Tailor Made Spirits Company Limited. She is a member of Audit & Risk Committee.
|Mr Terrence (Terry) Charles Budge||Non-Executive Director||Jan 2021|| |
Mr Budge has experience in senior management and board roles. A long term banker he spent 25 years with National Australia Bank in senior executive roles before serving as Managing Director of Bankwest from 1997 to 2004. Since then he has had many non-executive director roles including Chancellor of Murdoch University from 2006 to 2013. Terry is currently a director or Tiller Rides. He is the Chair of Risk Committee.
|Mr Geoffrey (Geoff) Richard Pocock||Non-Executive ChairmanNon-Executive Director||Nov 2019|| |
Mr Pocock has over 20 years experience across the commercialisation process. Geoff's experience has covered technical roles, executive management as well as significant corporate finance and strategy roles with a number of technology commercialisation ventures. Geoff is the Principal of Polaris Consulting (WA) Pty Ltd, a specialist boutique commercialisation strategy and corporate advisory business based in Western Australia. He is a member of Risk Committee.
|Dr Samantha (Sam) South||Executive Director||Mar 2020|| |
Dr South is currently the Senior Commercialisation Officer (Life Sciences) in the Research Development & Innovation office at The University of Western Australia (UWA) and has over 12 years' experience in technology transfer in medtech / biotech sector, at The University of Queensland (UQ), Queensland University of Technology and UWA. Sam has background in medical research at Weill Medical College at Cornell University (NY), UQ and The Garvan Institute in CNS research. She was also the Preclinical Manager at TetraQ, a preclinical contract organisation, specialising in central nervous system animal models. Sam was the UWA Director on UWA spin-out companies MiReven Pty Ltd, Eridan Technologies Pty Ltd and OncoRes Medical Pty Ltd and is currently a Director of Rage Biotech Pty Ltd. Sam is also WA Ausbiotech Committee Chair, part of the Ausmedtech National Advisory Group and the SBE Life Sciences Council.
|Dr Liz Dallimore||Chief Executive OfficerManaging Director||Apr 2022|| |
Dr Dallimore has over 20 years' experience across Australia and the UK with focus on research & development, innovation and commercialisation. Prior to joining Argenica Therapeutics, Dr Dallimore was the Director of the WA Data Science Innovation Hub, tasked with working across WA businesses to establish innovative data science projects. Dr Dallimore has also held senior roles in management consulting across Australia, most recently as KPMG's National Director of Research Engagement and Commercialization. Prior to this she held senior roles with Ernst & Young and PricewaterhouseCoopers. Dr Dallimore is a co-founder of medical device company Inspiring Holdings, sits on the AusBiotech WA Committee and is a non-executive Director of NERA, a Federal Government Growth Centre. She has worked as a neuroscientist at the Australian Neuromuscular Research Institute (now Perron Institute).
|Ms Emma Waldon||Chief Financial OfficerCompany Secretary|| |
|Emma Waldon||Chief Financial OfficerCompany Secretary|| |
|Oofy Prosser Pty Ltd <Drones Family A/C>||4,377,000||5.98%|
|University Of Western Australia||3,953,000||5.40%|
|Perron Institute For Neurological And Translational Science Ltd||3,550,000||4.85%|
|Shane Michael Colley <Fiery King Investment A/C>||2,000,000||2.73%|
|Arredo Pty Ltd||1,550,000||2.12%|
|Shane Hoehock Wee <Wee Family A/C>||1,544,000||2.11%|
|Litis Super Pty Ltd <Jde Litis Super Fund>||1,500,000||2.05%|
|Xcel Capital Pty Ltd||1,462,500||2.00%|
|Bruno Philip Meloni <Bruno Meloni Family A/C>||1,277,000||1.75%|
|Ga Skylight Berhad||1,250,000||1.71%|
|Ms Helen Margaret Sewell||1,225,000||1.67%|
|Mr Neville William Knuckey & Mrs Jacqueline Joy Knuckey <The Knuckey Family A/C>||1,072,000||1.47%|
|Busso Holdings Pty Ltd <Bew A/C>||1,025,000||1.40%|
|Pentek Holdings Pty Ltd <The J Litis Investment No.2 A/C>||785,000||1.07%|
|Hugh James Pilgrim <The Hjp Family A/C>||734,500||1.00%|
|Mr Paul Henri Veron & Mrs Julie Anne Veron <Dead Knick S/F A/C>||725,000||0.99%|
|Kdjama Co Pty Ltd <Blacker Services A/C>||655,750||0.90%|
|Quantamatics Pty Ltd||573,000||0.78%|
|Ms Chunyan Niu||500,000||0.68%|
|Mr Luke Daniel Ferguson||500,000||0.68%|